Proprietary DDS PlatformNanoCarrier’s proprietary nanoparticle DDS platform is a durable strategic asset that supports licensing and collaborative R&D. A platform approach enables recurring partnership revenue, easier extension across multiple drug candidates, and sustained competitive differentiation in nanomedicine.

High Gross MarginsSustained gross margins near 72% imply the core DDS technology has favorable unit economics when revenue is recognized. High gross margins provide structural capacity to absorb R&D and SG&A, improving the odds that operating leverage can drive profitability as revenue scales.

Manageable LeverageLow debt-to-equity (~0.20) and materially reduced absolute debt provide financial flexibility while the company executes R&D. This durable capital structure lowers immediate refinancing risk and interest burden, giving management room to pursue partnerships or non-dilutive funding.

Bears Say

Persistent Cash BurnConsistent negative operating cash flow and historical free cash flow deficits mean the company cannot self-fund operations or clinical programs. Continued cash burn forces reliance on external financing or partner funding, constraining strategic optionality and risking dilution over the medium term.

Shrinking Revenue & Large LossesMulti-year revenue declines combined with outsized operating and net losses (net margin ~-770% in FY2025) point to weak commercial traction and poor operating leverage. Structural revenue weakness makes it hard to scale R&D investment efficiently or achieve sustainable profitability.

Eroding Equity & Negative ROEDeclining shareholders' equity and ROE around -30% reflect cumulative losses that erode capital and investor value. Persistent negative returns reduce resilience to shocks, increase future financing needs, and raise the hurdle for management to restore capital-generation capability.

NanoCarrier Co., Ltd. News

Nano Holdings Begins First-in-Human mRNA Trial Targeting Knee Osteoarthritis

NanoCarrier Co., Ltd. ( ($JP:4571) ) has provided an announcement. Nano Holdings, Inc., a Japan-based healthcare value creation...

22d ago

NANO MRNA Advances RUNX1 mRNA Clinical Trial for Osteoarthritis

The latest announcement is out from NanoCarrier Co., Ltd. ( ($JP:4571) ). NANO MRNA Co., Ltd., through its...

6M ago

4571 FAQ

What was NanoCarrier Co., Ltd.’s price range in the past 12 months?

NanoCarrier Co., Ltd. lowest stock price was ¥113.00 and its highest was ¥254.00 in the past 12 months.

What is NanoCarrier Co., Ltd.’s market cap?

NanoCarrier Co., Ltd.’s market cap is ¥11.83B.

When is NanoCarrier Co., Ltd.’s upcoming earnings report date?

NanoCarrier Co., Ltd.’s upcoming earnings report date is May 20, 2026 which is in 57 days.

How were NanoCarrier Co., Ltd.’s earnings last quarter?

NanoCarrier Co., Ltd. released its earnings results on Feb 13, 2026. The company reported -¥2.86 earnings per share for the quarter, missing the consensus estimate of N/A by -¥2.86.

Is NanoCarrier Co., Ltd. overvalued?

According to Wall Street analysts NanoCarrier Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does NanoCarrier Co., Ltd. pay dividends?

NanoCarrier Co., Ltd. does not currently pay dividends.

What is NanoCarrier Co., Ltd.’s EPS estimate?

NanoCarrier Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does NanoCarrier Co., Ltd. have?

NanoCarrier Co., Ltd. has 75,374,160 shares outstanding.

What happened to NanoCarrier Co., Ltd.’s price movement after its last earnings report?

NanoCarrier Co., Ltd. reported an EPS of -¥2.86 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.797%.

Which hedge fund is a major shareholder of NanoCarrier Co., Ltd.?

Currently, no hedge funds are holding shares in JP:4571

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

NanoCarrier Co., Ltd.

NANO MRNA Co., Ltd. engages in the research, development, and production of pharmaceuticals using micellar nanoparticles technology. The company develops biopharmaceutical products focused on the medication of cancer and other intractable diseases. It also engages in the research, development, manufacture, and sale of anti-cancer drugs based on micellar nanoparticle technology. The company was founded by Kazunori Kataoka, Teruo Okano, and Ichiro Nakatomi on June 14, 1996 and is headquartered in Tokyo, Japan.